BCKDK and metabolic dysfunction-associated steatohepatitis: Thus, the inhibition of BCKDK is potentially an effective treatment for metabolic diseases such as NAFLD/NASH and hepatic cancer, and specific inhibitors targeting BCKDK have been explored.